Morgan Stanley Starts Enliven Therapeutics (ELVN) at Overweight

October 2, 2026 2:40 AM EDT Send to a Friend
Morgan Stanley analyst Sean Laaman initiates coverage on Enliven Therapeutics (NASDAQ: ELVN) with a Overweight rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login